Skip to main content

What the FDA labels say about taking them together

Doravirine/islatravir and pentostatin

Doravirine/islatravir's FDA label of April 20, 2026 names pentostatin in its drug interactions section; the pentostatin label PlainMeds reads does not name doravirine/islatravir. The doravirine/islatravir label: “Co-administration with pentostatin is not recommended as it may cause an increase in plasma concentrations of islatravir.”

Check it at the source: the doravirine/islatravir FDA label on DailyMed (effective April 20, 2026, Merck Sharp & Dohme LLC); the pentostatin FDA label on DailyMed (effective July 1, 2026, Hospira, Inc.).

What does the doravirine/islatravir label say about pentostatin?

Doravirine/islatravir label, drug interactions

Concomitant Drug Class/Drug Name: pentostatin; Effect on Concentration: ↑ islatravir; Clinical Comment: Co-administration with pentostatin is not recommended as it may cause an increase in plasma concentrations of islatravir.

Source: FDA drug label (IDVYNSO), NDA216964 (Msd), as published by Merck Sharp & Dohme LLC, effective April 20, 2026 (SPL set 11aaeb53-9848-433c-be7f-db8a5bc0b26f), via openFDA; the full label on DailyMed

What does the pentostatin label say about doravirine/islatravir?

Pentostatin's label (effective July 1, 2026) does not name doravirine/islatravir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Nipent), Hospira, Inc., effective July 1, 2026 (SPL set 674e0e6d-46ed-4868-9196-04019d667716), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Doravirine/islatravir generic labelers
0Pentostatin generic labelers
Doravirine/islatravirPentostatin
Labeled forHIVLeukemia, lymphoma and myeloma
Boxed warningNoYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryIn shortage

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?